NCT01230866进行中（未招募）3 期
A Phase III Prospective Randomized Trial of Standard-fractionation vs. Hypo-fractionation With Proton Radiation Therapy for Low Risk Adenocarcinoma of the Prostate
Proton Collaborative Group10 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2010年11月1日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
- 试验地点
- 10
- 主要终点
- To assess if hypo-fractionation will result in 2-year freedom from failure (FFF) that is non-inferior to 2-year FFF following standard fractionation. FFF will be measured by recurrence, metastasis, PSA or start of salvage therapy.
研究概览
简要总结
The purpose of this study is to compare the effects (good and bad) on patients with prostate cancer by comparing the standard dose of radiation therapy (44 treatments over 8½-9 weeks) with a higher daily dose of radiation (5 treatments over 1-2 weeks) to see if the effects of the treatments are similar or better.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed prostate adenocarcinoma within 365 days prior to randomization.
- •History/physical examination with digital rectal examination of the prostate and baseline toxicity assessment within 90 days prior to randomization.
- •Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material;Gleason score must be in the range of 2-
- •> 6 cores are strongly recommended.
- •PSA values < 10 ng/ml within 90 days prior to randomization. Either done prior to biopsy or at least 21 days after prostate biopsy.
- •Clinical stages T1a-T2a N0 M0 (AJCC Criteria 7th Ed.). Staging must be done by treating investigator.
- •No pelvic lymph nodes > 1.5 cm in greatest dimension unless the enlarged lymph node is biopsied and negative.
- •Patients must be at least 18 years old.
- •ECOG performance status 0-1 (appendix I) documented within 90 days prior to randomization.
- •IPSS score <=
- •Patients must give IRB approved, study specific, informed consent.
- •Patients must complete all mandatory tests listed in section 4.0 within the specified time frames.
- •Patients must be able to start treatment within 56 days of randomization.
排除标准
- •Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery.
- •Previous pelvic radiation for prostate cancer.
- •Androgen deprivation therapy prior to radiation is allowed. However, it is not acceptable if continued during radiation or as adjuvant therapy.
- •Active rectal diverticulitis, Crohn's disease affecting the rectum, or ulcerative colitis.
- •Prior systemic chemotherapy for prostate cancer.
- •History of proximal urethral stricture requiring dilatation.
- •Current and continuing anticoagulation with warfarin sodium (Coumadin, heparin, low-molecular weight heparin, Clopidogrel bisulfate (Plavix),or equivalent. (Unless it can be stopped to manage treatment related toxicity, to have a biopsy if needed, or for marker placement).
- •Any major medical, addictive or psychiatric illnesses which would affect the consent process, completion of treatment and/or interfere with follow-up. Consent by legal authorized representative is not permitted in this study.
- •Evidence of any other cancer within the past 5 years and < 50% probability of a 5 year survival. (Prior or concurrent diagnosis of basal cell or non-invasive squamous cell cancer of the skin is allowed).
结局指标
主要结局
To assess if hypo-fractionation will result in 2-year freedom from failure (FFF) that is non-inferior to 2-year FFF following standard fractionation. FFF will be measured by recurrence, metastasis, PSA or start of salvage therapy.
时间窗: At 5 years post treatment completion +/- 90 days
The events for FFF will be the first occurrence of clinical failure (local recurrence, regional recurrence, or distant metastasis), biochemical failure by the Phoenix definition (PSA ≥ 2 ng/ml over the current nadir PSA),or the start of salvage therapy including androgen deprivation.
次要结局
- To determine the incidence of grade 2 or greater GU and GI toxicity in each of the regimens.(At 6 months and 2 years post randomization)
研究者
研究点 (10)
Loading locations...
相似试验
已完成
3 期
Study of Immunotherapy to Treat Advanced Prostate CancerProstate CancerNCT00861614Bristol-Myers Squibb988
已完成
3 期
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer PatientsProstate CancerNCT00884273Ferring Pharmaceuticals182
Unknown
3 期
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation TherapyProstate CancerNCT00175396University of British Columbia400
已完成
3 期
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate CancerProstate CancerNCT01809691SWOG Cancer Research Network1,313
招募中
2 期
ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate CancerProstate CancerNCT06397703NYU Langone Health392